SPOTLIGHT -
Future Directions for the Management of Advanced Prostate Cancer
Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Role of PSMA PET in Advanced Prostate Cancer Management
Experts in prostate cancer review the role of PSMA PET imaging in advanced prostate cancer and its impact on disease management.
Managing AEs for ARI Therapy in Advanced Prostate Cancer
Bobby Liaw, MD, and Vivek K. Narayan, MD, MS, share clinical pearls for the management of adverse events from ARI-directed therapy in advanced prostate cancer.
Role of PSA Kinetics in nmCRPC Management
Ashley E. Ross, MD, PhD, comments on the clinical significance of PSA response in patients with nmCRPC.
Phase 3 SPARTAN Trial in nmCRPC
Vivek K. Narayan, MD, MS, reviews data from the SPARTAN trial in nmCRPC and discusses the importance of assessing health-related quality of life.
PROSPER and ARAMIS Trials in nmCRPC
Ashley E. Ross, MD, PhD, discusses challenges and unmet needs in managing nmCRPC and Bobby Liaw, MD, reviews the PROSPER and ARAMIS trials.
Approaching Treatment of mCSPC
Vivek K. Narayan, MD, MS, shares thoughts on approaching treatment selection of mCSPC and Ashley E. Ross, MD, PhD, comments on the use of relugolix in patients.
ENZAMET and ARASENS Trials in mCSPC
Bobby Liaw, MD, reviews the study design and results of the phase 3 ENZAMET study and discusses an ongoing trial in mCSPC, ARASENS.
TITAN and ARCHES Trials in mCSPC
Ashley E. Ross, MD, PhD, reviews data and study results from the phase 3 TITAN and phase 3 ARCHES trial in mCSPC.
Evolution of Care of mCSPC
Vivek K. Narayan, MD, MS, provides insight on the evolution of care for mCSPC and the current use of ARI-directed therapy for disease management.
Advanced Prostate Cancer: Mediating Treatment Through Multidisciplinary Management
Experts in prostate cancer comment on the role of urologists in performing molecular testing and share how they facilitate treatment of advanced prostate cancer across multiple disciplines.
Risk Stratification in Advanced Prostate Cancer
Ashley E. Ross, MD, PhD, leads the discussion on risk stratification in advanced prostate cancer and approaching prostate cancer screening.
Incidence of Advanced Prostate Cancer
Bobby Liaw, MD; Neal Shore, MD, FACS; and Vivek K. Narayan, MD, MS, discuss the incidence and prevalence of advanced prostate cancer, including mCSPC and nmCRPC.